Comprehensive Guide: EUS-Guided Celiac Plexus Neurolysis (CPN)

1. Introduction and Overview

Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) represents a sophisticated interventional endoscopy technique designed primarily for the management of intractable abdominal pain associated with pancreatic malignancy. By targeting the celiac plexus—a dense network of nerves located behind the pancreas that transmits pain signals from the upper abdominal viscera to the central nervous system—EUS-CPN provides a minimally invasive, targeted chemical denervation.

Unlike systemic pharmacological management, which often involves high-dose opioids and their attendant side effects (constipation, sedation, cognitive impairment), CPN offers a localized approach. By injecting a neurolytic agent (typically absolute alcohol) directly into the celiac plexus, the procedure interrupts pain transmission, significantly improving the quality of life for patients with pancreatic cancer.

2. Technical Specifications and Mechanism of Action

The Anatomical Target

The celiac plexus is a collection of ganglia and nerve fibers situated anterior to the aorta and posterior to the pancreas, surrounding the origin of the celiac trunk. It receives sympathetic input from the greater and lesser splanchnic nerves and provides sympathetic/parasympathetic innervation to the stomach, liver, gallbladder, spleen, kidneys, and pancreas.

The Mechanism of Neurolysis

The procedure utilizes the precision of high-frequency endosonography. A linear-array echoendoscope is positioned in the stomach, identifying the celiac trunk and the celiac ganglia.
* The Neurolytic Agent: Absolute ethanol (98% dehydrated alcohol) is the gold standard. It induces coagulation necrosis of the nerve fibers and ganglia, causing protein denaturation and cellular dehydration.
* The Adjunct: Bupivacaine or lidocaine is often injected prior to the alcohol to provide local anesthesia and potentially reduce the incidence of post-procedural pain flares.

3. Clinical Indications and Usage

EUS-CPN is not a curative cancer treatment; it is a palliative intervention. The primary indications include:

Primary Indications

1. Pancreatic Adenocarcinoma: Specifically for patients with unresectable tumors causing severe, opioid-refractory pain.
2. Chronic Pancreatitis (Celiac Plexus Block): While "Neurolysis" implies permanent destruction (cancer), "Block" (utilizing corticosteroids) is sometimes used for non-malignant pain, though efficacy is more controversial.
3. Metastatic Disease: Palliative management in patients with gastric cancer or other upper GI malignancies invading the celiac axis.

Patient Selection Criteria

• Pain Profile: Visceral pain localized to the upper abdomen.
• Refractory Status: Failure of, or intolerance to, Step 3 WHO analgesic ladder medications.
• Anatomical Feasibility: Absence of vascular invasion or anatomical distortion that precludes safe needle passage.

4. Pre-Procedural Preparation and Protocol

Successful EUS-CPN requires a multidisciplinary approach involving gastroenterology, anesthesiology, and oncology.

Pre-Op Checklist

• Coagulation Profile: Patients must have an INR < 1.5 and a platelet count > 50,000/mm³. Anticoagulants/antiplatelets must be held according to ASGE guidelines.
• Imaging Review: Review of CT/MRI to assess the location of the celiac trunk and rule out major vessel involvement at the injection site.
• Antibiotic Prophylaxis: While controversial, many centers administer a single dose of prophylactic antibiotics (e.g., Ciprofloxacin) due to the risk of retroperitoneal infection.
• Sedation: Deep sedation (propofol) or general anesthesia is required to ensure patient immobility during the delicate injection phase.

5. Detailed Procedure Steps

The procedure is performed in an endoscopy suite equipped with high-resolution EUS capabilities.

1. Access: The echoendoscope is advanced into the stomach and positioned in the gastric body or fundus.
2. Visualization: The celiac trunk is identified arising from the aorta. The celiac ganglia are identified as hypoechoic, slightly irregular structures surrounding the trunk.
3. Needle Placement: A 19G or 22G fine-needle aspiration (FNA) needle is advanced through the gastric wall into the space adjacent to the celiac trunk.
4. Aspiration: Crucial step—the needle is aspirated to ensure it is not located within a major blood vessel (the aorta or celiac artery).
5. Anesthetic Injection: 5–10 mL of Bupivacaine (0.25% or 0.5%) is injected to verify needle position and provide local analgesia.
6. Neurolysis: 10–20 mL of absolute alcohol (98% ethanol) is injected slowly. The physician monitors for "spread" of the echogenic fluid around the celiac trunk under EUS guidance.
7. Withdrawal: The needle is withdrawn, and the gastric wall puncture site is inspected for active bleeding.

6. Post-Procedural Recovery and Protocol

Immediate Recovery

• Monitoring: Patients remain in a recovery unit for 2–4 hours. Vital signs are monitored for signs of hypotension or excessive pain.
• Diet: Clear liquids may be initiated once the patient is fully alert.

Common Transient Side Effects

• Pain Flare: A transient increase in abdominal pain may occur within the first 24–48 hours due to the inflammatory reaction of the alcohol.
• Diarrhea: Occurs in approximately 15–20% of patients due to the temporary interruption of sympathetic tone to the gut, leading to parasympathetic dominance (increased peristalsis).

7. Risks, Complications, and Contraindications

While EUS-CPN is generally safe, the proximity to major retroperitoneal structures carries inherent risks.

Potential Complications

• Procedural Pain: Severe transient pain during injection.
• Hypotension: Due to the "chemical sympathectomy" effect.
• Neurological Deficits: Rare, but potential for paraplegia if the neurolytic agent tracks into the spinal artery (radicular artery).
• Retroperitoneal Infection: Rare abscess formation.
• Vascular Injury: Bleeding from the aorta or celiac artery.

Contraindications

• Absolute: Uncorrectable coagulopathy, active infection, or inability to safely position the scope.
• Relative: Severe anatomical distortion (e.g., previous gastric bypass, large tumor mass obstructing the gastric lumen).

8. Alternative Treatments

When EUS-CPN is not feasible or effective, the following alternatives exist:
1. Systemic Analgesics: Escalation to potent opioids (fentanyl patches, methadone).
2. Radiation Therapy: External beam radiotherapy to the tumor mass to reduce bulk and associated nerve compression.
3. Percutaneous CPN: Performed by interventional radiology under CT guidance. This is often an alternative if the endoscopic route is blocked by the tumor.
4. Surgical Neurolysis: Rarely performed today due to the invasiveness of open or laparoscopic surgery compared to EUS.

9. Frequently Asked Questions (FAQ)

1. Is EUS-CPN a cure for pancreatic cancer?

No. It is a strictly palliative procedure intended to reduce pain and improve quality of life. It does not treat the tumor itself.

2. How long does the pain relief last?

For most patients, the relief is significant for 3 to 6 months. In cases of advanced disease, it may last for the remainder of the patient's life.

3. Why does diarrhea occur after the procedure?

The celiac plexus contains sympathetic nerves that inhibit intestinal motility. Destroying these nerves allows the parasympathetic nervous system to take over, causing increased bowel movements.

4. Is the procedure painful?

The procedure is performed under deep sedation, so the patient feels nothing during the injection. Some patients experience a "flare" of pain for 1–2 days afterward.

5. Can it be repeated?

Yes. If the pain returns, a repeat CPN can be performed, though technical difficulty may increase due to fibrosis from the first procedure.

6. What is the success rate?

Reported success rates for pain reduction range from 70% to 90% in appropriately selected patients.

7. Does it replace all opioid medication?

Often, it allows for a significant reduction in the dosage of opioids, which helps clear the patient's mental state, but it rarely eliminates the need for all pain medication.

8. What are the risks of using alcohol?

Absolute alcohol is highly effective but can cause localized tissue damage if it leaks into the wrong area. This is why EUS visualization is vital.

9. How do I know if I am a candidate?

Candidates are typically identified by a multidisciplinary tumor board, specifically those with unresectable pancreatic cancer and pain that is not controlled by standard oral medications.

10. Are there any dietary restrictions after the procedure?

Generally, no. However, due to the potential for diarrhea, some clinicians recommend a low-residue diet for the first few days post-procedure.

10. Summary Table: Outcomes and Expectations

Disclaimer: This guide is for educational purposes for clinical professionals. All interventional procedures must be performed by board-certified gastroenterologists or interventional endoscopists in a hospital setting with appropriate support staff and emergency equipment available.